Clinical approach to fertility making-decisions in breast cancer patients
Abstract
Fertility it’s an important issue in breast cancer (BC) patients. Twenty-five percent of the patients with BC are premenopausal at diagnosis, Decision-making about fertility in young women with BC, is complex and extremely important for their future as mothers. Adjuvant chemotherapy is extensively used in premenopausal patients because of its overwhelming beneficial affects of outcome. Chemotherapy induces amenorrhea (CIA). The incidence of CIA, it’s in relation with the patient age, drug, dose and number of cycles In addition to considerations related to presentation of disease, prognosis, and treatment, young women with BC faces various problems, one of them it is their fertility. When chemotherapy is indicated the preservation of ovarian function should be considered. Experimental procedures to retain fertility after BC by cry preservation of unfertilized eggs or embryons or ovarian tissues are now on study. As is a very important question for BC young women, fertility after treatments or BC should be discussed before planning of adjuvant therapies It should be based on a model of attention where the patients could take an informed decision as a cancer long survivor about their fertility .The oncologist could have problems to offer the possibility to preserve the patients fertility, and also the patients can have same personal problems that make diffi cult to take this decision.. This work describes the different medical options, aspects of communication and psychological ways that mediate this entire process.Downloads
Article download
License
In order to support the global exchange of knowledge, the journal Psicooncología is allowing unrestricted access to its content as from its publication in this electronic edition, and as such it is an open-access journal. The originals published in this journal are the property of the Complutense University of Madrid and any reproduction thereof in full or in part must cite the source. All content is distributed under a Creative Commons Attribution 4.0 use and distribution licence (CC BY 4.0). This circumstance must be expressly stated in these terms where necessary. You can view the summary and the complete legal text of the licence.




